MedPath

Nicotinamide

Generic Name
Nicotinamide
Brand Names
Alertonic, Fortaplex, Infuvite, Infuvite Pediatric, Mvc-fluoride, Mvi Pediatric, Natafort, Neo-bex, Nicomide, Pregvit, Tandem Plus
Drug Type
Small Molecule
Chemical Formula
C6H6N2O
CAS Number
98-92-0
Unique Ingredient Identifier
25X51I8RD4
Background

An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.

Indication

用于防治糙皮病等烟酸缺乏病，也用于防治心脏传导阻滞。

Associated Conditions
Gastrointestinal insufficiency, Hepatic Insufficiency, Macrocytic anemia, Secondary anemia, Vitamin Deficiency, Severe debilitation
Associated Therapies
Dietary and Nutritional Therapies, Nutritional supplementation, Dietary supplementation
Clinical Trials
Related News

The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE

Phase 2
Completed
Conditions
Chronic Kidney Disease
Interventions
Drug: Nicotinamide
Drug: Placebo (for Nicotinamide)
Drug: Placebo (for lanthanum carbonate)
Drug: Lanthanum Carbonate
First Posted Date
2014-10-07
Last Posted Date
2021-08-02
Lead Sponsor
The Cleveland Clinic
Target Recruit Count
205
Registration Number
NCT02258074
Locations
🇺🇸

NorthShore University Health System, Chicago, Illinois, United States

🇺🇸

Denver Nephrology Research, Denver, Colorado, United States

🇺🇸

Northwestern University, Chicago, Illinois, United States

and more 4 locations

Phase I Study of Nicotinamide for Early Onset Preeclampsia

Phase 1
Completed
Conditions
Pregnancy Induced Hypertension
Hypertension
Superimposed Preeclampsia
Interventions
Drug: Nicotinamide 1000 mg
Drug: Nicotinamide 500 mg
First Posted Date
2014-08-11
Last Posted Date
2018-11-02
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
10
Registration Number
NCT02213094
Locations
🇺🇸

University of North Carolina Women's Hospital, Chapel Hill, North Carolina, United States

Effect of Nicotinamide in Friedreich's Ataxia

Phase 2
Conditions
Neurodegenerative Disorders
Interventions
Drug: nicotinamide
First Posted Date
2012-05-02
Last Posted Date
2017-07-02
Lead Sponsor
Imperial College London
Target Recruit Count
40
Registration Number
NCT01589809
Locations
🇬🇧

National Hospital for Neurology and Neurosurgery, London, United Kingdom

🇬🇧

NIHR/Wellcome Trust Imperial CRF, London, Hammersmith, United Kingdom

Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation

Phase 4
Completed
Conditions
Hyperpigmentation
Interventions
Drug: Niacinamide
Drug: Placebo
Drug: Desonide
First Posted Date
2012-03-02
Last Posted Date
2012-11-29
Lead Sponsor
Universidad Autonoma de San Luis Potosí
Target Recruit Count
28
Registration Number
NCT01542138
Locations
🇲🇽

Dermatology Department. Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosi, Mexico

Nicotinamide in Hemodialysis Patients With Hyperphosphatemia

Phase 2
Completed
Conditions
Chronic Kidney Disease
Hemodialysis
Hyperphosphatemia
Interventions
Drug: Nicotinamide
First Posted Date
2010-09-14
Last Posted Date
2012-01-18
Lead Sponsor
Medice Arzneimittel Pütter GmbH & Co KG
Target Recruit Count
252
Registration Number
NCT01200784

Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients

Phase 3
Terminated
Conditions
Chronic Renal Failure
Hemodialysis
Interventions
Drug: nicotinamide
Drug: sevelamer
Drug: cinacalcet
First Posted Date
2009-11-11
Last Posted Date
2016-05-16
Lead Sponsor
Centre Hospitalier Universitaire, Amiens
Target Recruit Count
176
Registration Number
NCT01011699
Locations
🇫🇷

ALURAD, Limoges, Limousin, France

🇫🇷

Centre Hospital-Universitaire d'Amiens, Amiens, Picardie, France

🇫🇷

Centre Hospitalier, Cambrai, France

and more 10 locations

Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies

Phase 1
Completed
Conditions
Non-Hodgkin's Lymphoma
Hodgkin's Disease
Interventions
Drug: Vorinostat
Drug: Niacinamide
Drug: Etoposide
First Posted Date
2008-06-05
Last Posted Date
2020-11-20
Lead Sponsor
Columbia University
Target Recruit Count
40
Registration Number
NCT00691210
Locations
🇺🇸

Center for Lymphoid Malignancies at CUMC, New York, New York, United States

Safety Study of Nicotinamide to Treat Alzheimer's Disease

Phase 1
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: Enduramide placebo
Drug: Nicotinamide
First Posted Date
2007-12-27
Last Posted Date
2017-01-25
Lead Sponsor
University of California, Irvine
Target Recruit Count
50
Registration Number
NCT00580931
Locations
🇺🇸

UC Irvine School of Medicine, Irvine, California, United States

The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients

Phase 1
Completed
Conditions
Hyperphosphatemia
Interventions
Drug: Placebo
Drug: Niacinamide
First Posted Date
2007-07-30
Last Posted Date
2007-07-30
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
17
Registration Number
NCT00508885
Locations
🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients

Phase 1
Completed
Conditions
Hyperphosphatemia
First Posted Date
2006-04-20
Last Posted Date
2009-01-16
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
40
Registration Number
NCT00316472
Locations
🇺🇸

Washington University Medical Center, Saint Louis, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy